Prenetics
Aims to give millions of people personalized information about the health of their bodies to help them confidently make choices about their lives.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | N/A | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 606 % | 323 % | - | (92 %) | 41 % | 195 % | 60 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1 %) | (59 %) | 16 % | (190 %) | (135 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (3 %) | (63 %) | (69 %) | (288 %) | (151 %) | (41 %) | (11 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4 % | 4 % | 6 % | 54 % | 36 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Prenetics is a biotechnology company specializing in genetic testing and COVID-19 diagnostics. Utilizing Whole Exome Sequencing Technology and the Illumina NovaSeqTM 6000 system, Prenetics offers comprehensive and accurate genetic insights through its CircleDNA product. This service provides users with detailed reports on diet, nutrition, fitness, stress, sleep needs, and risks for various diseases, including cancer. Additionally, Prenetics runs Project Screen, a COVID-19 testing initiative in Hong Kong and the UK, backed by industry leaders such as Prudential and The Doctors Laboratory. The company serves individual consumers seeking personalized health information and preventive care solutions. Prenetics operates in the health and biotechnology market, generating revenue through the sale of genetic testing kits and COVID-19 diagnostic services. The business model is direct-to-consumer, with a focus on providing actionable health insights based on genetic data.
Keywords: genetic testing, COVID-19 diagnostics, Whole Exome Sequencing, personalized health, preventive care, CircleDNA, Project Screen, biotechnology, health insights, direct-to-consumer.
Tech stack
Investments by Prenetics
Edit
